English
简体中文
Total: £ 56.28
Published Date: 2026-03-27 | Pages: 114 | Tables: 117 | Pharma & Healthcare
The global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Poly (ADP-Ribose) Polymerase (PARP) Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors include Pfizer, AstraZeneca, Merck & Co, Myriad Genetics, GlaxoSmithKline, Johnson & Johnson, AbbVie, Teva Pharmaceutical Industries, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Poly (ADP-Ribose) Polymerase (PARP) Inhibitors. The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Poly (ADP-Ribose) Polymerase (PARP) Inhibitors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
AstraZeneca
Merck & Co
Myriad Genetics
GlaxoSmithKline
Johnson & Johnson
AbbVie
Teva Pharmaceutical Industries
Segment by Type
Talazoparib
Veliparib
Olaparib
Other
by Application
Ovarian Cancer
Breast Cancer
Fallopian Tube Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Poly (ADP-Ribose) Polymerase (PARP) Inhibitors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
1.1 Product Definition
1.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type
1.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Talazoparib
1.2.3 Veliparib
1.2.4 Olaparib
1.2.5 Other
1.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application
1.3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Fallopian Tube Cancer
1.3.5 Other
1.4 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue 2021–2032
1.4.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales 2021–2032
1.4.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competition by Manufacturers
2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Date of Entry into the Industry
2.8 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Situation and Trends
2.8.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Players Market Share by Revenue
2.8.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Scenario by Region
3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2021–2032
3.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2021–2026
3.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2027–2032
3.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2027–2032
3.4 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country
3.4.1 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2021–2032)
3.4.3 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country
3.5.1 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2021–2032)
4.1.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2021–2026)
4.1.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2027–2032)
4.1.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2021–2032)
5.1.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2021–2026)
5.1.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2027–2032)
5.1.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Company Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 Myriad Genetics
6.4.1 Myriad Genetics Company Information
6.4.2 Myriad Genetics Description and Business Overview
6.4.3 Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.4.5 Myriad Genetics Recent Developments/Updates
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Company Information
6.5.2 GlaxoSmithKline Description and Business Overview
6.5.3 GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.5.5 GlaxoSmithKline Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Company Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 AbbVie
6.7.1 AbbVie Company Information
6.7.2 AbbVie Description and Business Overview
6.7.3 AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.7.5 AbbVie Recent Developments/Updates
6.8 Teva Pharmaceutical Industries
6.8.1 Teva Pharmaceutical Industries Company Information
6.8.2 Teva Pharmaceutical Industries Description and Business Overview
6.8.3 Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio
6.8.5 Teva Pharmaceutical Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry Chain Analysis
7.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Production Mode & Process Analysis
7.4 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales and Marketing
7.4.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Channels
7.4.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Distributors
7.5 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Customer Analysis
8 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Dynamics
8.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry Trends
8.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Drivers
8.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Challenges
8.4 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Pfizer Company Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 74. Pfizer Recent Developments/Updates
Table 75. AstraZeneca Company Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Merck & Co Company Information
Table 81. Merck & Co Description and Business Overview
Table 82. Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 84. Merck & Co Recent Developments/Updates
Table 85. Myriad Genetics Company Information
Table 86. Myriad Genetics Description and Business Overview
Table 87. Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 89. Myriad Genetics Recent Developments/Updates
Table 90. GlaxoSmithKline Company Information
Table 91. GlaxoSmithKline Description and Business Overview
Table 92. GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 94. GlaxoSmithKline Recent Developments/Updates
Table 95. Johnson & Johnson Company Information
Table 96. Johnson & Johnson Description and Business Overview
Table 97. Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 99. Johnson & Johnson Recent Developments/Updates
Table 100. AbbVie Company Information
Table 101. AbbVie Description and Business Overview
Table 102. AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 104. AbbVie Recent Developments/Updates
Table 105. Teva Pharmaceutical Industries Company Information
Table 106. Teva Pharmaceutical Industries Description and Business Overview
Table 107. Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product
Table 109. Teva Pharmaceutical Industries Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Distributors List
Table 113. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Customers List
Table 114. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends
Table 115. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Drivers
Table 116. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Challenges
Table 117. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
Figure 2. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Talazoparib Product Picture
Figure 5. Veliparib Product Picture
Figure 6. Olaparib Product Picture
Figure 7. Other Product Picture
Figure 8. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Application: 2025 & 2032
Figure 10. Ovarian Cancer
Figure 11. Breast Cancer
Figure 12. Fallopian Tube Cancer
Figure 13. Other
Figure 14. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size (US$ Million), 2021–2032
Figure 16. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), 2021–2032
Figure 17. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price (US$/Unit), 2021–2032
Figure 18. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Report Years Considered
Figure 19. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Share by Manufacturers in 2025
Figure 20. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Players: Market Share by Revenue in Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in 2025
Figure 22. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2021–2032)
Figure 25. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2021–2032)
Figure 26. United States Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2021–2032)
Figure 29. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2021–2032)
Figure 30. Germany Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2021–2032)
Figure 37. China Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2021–2032)
Figure 45. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type (2021–2032)
Figure 56. Global Revenue Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type (2021–2032)
Figure 57. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application (2021–2032)
Figure 59. Global Revenue Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application (2021–2032)
Figure 60. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 61. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
